Senseonics Holdings, Inc. (SENS) Dividend History

Senseonics Holdings, Inc. (SENS) is a medical technology company that develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Known for its implantable Eversense CGM system, the company aims to improve diabetes management through innovative, long-term sensor solutions that provide real-time glucose data.

Dividend History

Senseonics Holdings, Inc. currently does not pay dividends

Company News

Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters’ Option to Purchase Additional Shares, and Closing of Private Placement

Senseonics Holdings, Inc. announced the closing of a public offering of 115 million shares of its common stock, raising $57.5 million in gross proceeds. The company also closed a private placement with Abbott Laboratories, who acquired 40.5 million shares for $20.3 million. The proceeds will be used to fund the launch of Eversense 365 and development of pipeline products.

GlobeNewswire Inc.

Featured Companies: ABT
Diabetic Care Device Market Set for Significant Growth with 10.1% CAGR

The global diabetes care devices market is expected to grow from $15.3 billion in 2023 to $26.8 billion by 2029, driven by the rising prevalence of diabetes and the increasing adoption of advanced technologies like continuous glucose monitoring systems.

GlobeNewswire Inc.

Featured Companies: ABT DXCM MDT
Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting

Senseonics reported strong preliminary 2024 results, including revenue growth and increased patient base. The company also received FDA approval for its Eversense 365 CGM system and saw positive early launch indicators. However, the company has decided to cancel a previously announced special meeting to consider a reverse stock split.

GlobeNewswire Inc.
Eversense 365 Receives FDA Clearance: The World’s First One Year CGM

The FDA has cleared the Eversense 365 CGM system, which provides one year of continuous glucose monitoring for people with diabetes. This represents a significant breakthrough in diabetes technology, offering longer sensor life, improved accuracy, and seamless integration with other devices.

GlobeNewswire Inc.
[Latest] US Diabetes Devices Market Size/Share Worth USD - GlobeNewswire

The US diabetes devices market is expected to grow from $5.4 billion in 2023 to $19.8 billion by 2033, driven by trends in integration, user-friendly designs, and personalized medicine.

GlobeNewswire Inc.

Featured Companies: ABT BDX DXCM JNJ LLY MDT PODD TNDM

Dividend data last updated 06/07/2025 21:55:48 UTC